Arun Kashyap

About

I am a research leader in biotechnology, currently serving as the Sr. Vice President, Oncology for Nitrase Therapeutics. My career has been focused on the discovery and development of mainly biologic and peptide therapeutics for anemia, influenza prophylaxis and therapy, inflammatory diseases (IBD and IBS), and cancer. I have led research groups in these efforts as well as in recombinant antibody and peptide technology development for over 15 years. This has included staffing, budget planning and management, goal setting and tracking, collaboration establishment and management, patent filing and intellectual property management, internal and external communication of research results through peer reviewed publications, posters and conference presentations.

Employment

• Nitrase Therapeutics Sr. Vice President
  2022 - Present
• Arch Oncology Vice President
  2020 - 2022
• Dren Bio Sr. Director
  2019 - 2020
• Compugen USA Inc Director
  2016 - 2019
• Protagonist Therapeutics (United States) Research Fellow
  2012 - 2014
• Sealane Biotechnologies Investigator and Director
  2008 - 2012
• Sealane Biotechnologies Principal Scientist
  2006 - 2008
• BD Biosciences BioProcess Engineer II
  2004 - 2006
• Kelly Scientific Resources Contractor
  2004 - 2004
• Pharmagenesis Inc Scientist
  2001 - 2003
• Affymax Research Institute Research Associate
  1992 - 1995
• Sandoz Agro, Inc Scientist
  1990 - 1992

Education

• University of California, Santa Cruz PhD
  1995 - 2001
• University of California, Berkeley AB
  1983 - 1989

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• Unveiling the human nitroproteome: Protein tyrosine nitration in cell signaling and cancer
  Journal of Biological Chemistry 2023 DOI: 10.1016/j.jbc.2023.105038
  +Save
• Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
  Molecular cancer therapeutics 2015 DOI: 10.1158/1535-7163.mct-15-0400
  +Save
• Cross-neutralization of influenza A viruses mediated by a single antibody loop.
  Nature 2012 DOI: 10.1038/nature11414
  +Save
• Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.
  PLoS pathogens 2010 DOI: 10.1371/journal.ppat.1000990
  +Save
• Surrobodies with functional tails.
  Journal of molecular biology 2010 DOI: 10.1016/j.jmb.2010.01.036
  +Save
• Combinatorial surrobody libraries.
  Proceedings of the National Academy of Sciences of the United States of America 2008 DOI: 10.1073/pnas.0805293105
  +Save
• Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.
  Proceedings of the National Academy of Sciences of the United States of America 2008 DOI: 10.1073/pnas.0801367105
  +Save
• Biochemical and genetic characterization of Yra1p in budding yeast.
  Yeast (Chichester, England) 2005 DOI: 10.1002/yea.1185
  +Save
• Increased potency of an erythropoietin peptide mimetic through covalent dimerization.
  Nature biotechnology 1997 DOI: 10.1038/nbt1197-1261
  +Save
• Small peptides as potent mimetics of the protein hormone erythropoietin.
  Science (New York, N.Y.) 1996 DOI: 10.1126/science.273.5274.458
  +Save